Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX.

ABSTRACT:

Objective

To examine the role of adenosine receptor 2a gene (ADORA2a) polymorphisms on outcome of MTX treatment in RA.

Methods

Subjects included 309 RA patients with a defined response to MTX. Patients were included if they were (i) good responders (n = 147) (ESR <20 for >6/12 on stable dose of MTX) (ii) inefficacy failures (n = 101) (physician statement and failure to reduce ESR/CRP by 20%) or (iii) adverse event (AE) failures (n = 61) (verified by medical record review). AEs were sub-divided into gastrointestinal (GI) (n = 24), abnormal LFTs (n = 20) or other (n = 17). 8 single nucleotide polymorphisms (SNPs) within ADORA2a were genotyped using the Sequenom MALDI-TOF platform.

Results

Five SNPs within ADORA2a were associated with stopping MTX for AEs (OR 2.1-3.07, P

SUBMITTER: Hider SL 

PROVIDER: S-EPMC2468887 | biostudies-literature | 2008 Aug

REPOSITORIES: biostudies-literature